Journal of Gastric Cancer

The Korean Gastric Cancer Association (대한위암학회)
권호 표지
DOI QR코드

DOI QR Code

Tumor Location Causes Different Recurrence Patterns in Remnant Gastric Cancer

  • Sun, Bo (Department of Gastric Surgery, Fudan University Shanghai Cancer Center) ;
  • Zhang, Haixian (Department of Oncology, Shanghai Medical College of Fudan University) ;
  • Wang, Jiangli (Department of Gastric Surgery, Fudan University Shanghai Cancer Center) ;
  • Cai, Hong (Department of Gastric Surgery, Fudan University Shanghai Cancer Center) ;
  • Xuan, Yi (Department of Gastric Surgery, Fudan University Shanghai Cancer Center) ;
  • Xu, Dazhi (Department of Gastric Surgery, Fudan University Shanghai Cancer Center)
  • Received : 2022.06.01
  • Accepted : 2022.08.13
  • Published : 2022.10.31
Download PDF
⟨ Previous Next ⟩

Abstract

Purpose: Tumor recurrence is the principal cause of poor outcomes in remnant gastric cancer (RGC) after resection. We sought to elucidate the recurrent patterns according to tumor locations in RGC. Materials and Methods: Data were collected from the Shanghai Cancer Center between January 2006 and December 2020. A total of 129 patients with RGC were included in this study, of whom 62 had carcinomas at the anastomotic site (group A) and 67 at the non-anastomotic site (group N). The clinicopathological characteristics, surgical results, recurrent diseases, and survival were investigated according to tumor location. Results: The time interval from the previous gastrectomy to the current diagnosis was 32.0±13.0 and 21.0±13.4 years in groups A and N, respectively. The previous disease was benign in 51/62 cases (82.3%) in group A and 37/67 cases (55.2%) in group N (P=0.002). Thirty-three patients had documented sites of tumor recurrence through imaging or pathological examinations. The median time to recurrence was 11.0 months (range, 1.0-35.1 months). Peritoneal recurrence occurred in 11.3% (7/62) of the patients in group A versus 1.5% (1/67) of the patients in group N (P=0.006). Hepatic recurrence occurred in 3.2% (2/62) of the patients in group A versus 13.4% (9/67) of the patients in group N (P=0.038). Patients in group A had significantly better overall survival than those in group N (P=0.046). Conclusions: The tumor location of RGC is an essential factor for predicting recurrence patterns and overall survival. When selecting an optimal postoperative follow-up program for RGC, physicians should consider recurrent features according to the tumor location.

Keywords

Acknowledgement

This study was supported by the National Natural Science Foundation of China (Grant No. 81902436).

References

  1. Tanigawa N, Nomura E, Lee SW, Kaminishi M, Sugiyama M, Aikou T, et al. Current state of gastric stump carcinoma in Japan: based on the results of a nationwide survey. World J Surg 2010;34:1540-1547. https://doi.org/10.1007/s00268-010-0505-5
  2. An JY, Youn HG, Ha TK, Choi MG, Kim KM, Noh JH, et al. Clinical significance of tumor location in remnant gastric cancers developed after partial gastrectomy for primary gastric cancer. J Gastrointest Surg 2008;12:689-694. https://doi.org/10.1007/s11605-007-0437-z
  3. Takahashi M, Takeuchi H, Tsuwano S, Nakamura R, Takahashi T, Wada N, et al. Surgical resection of remnant gastric cancer following distal gastrectomy: a retrospective clinicopathological study. Ann Surg Oncol 2016;23:511-521. https://doi.org/10.1245/s10434-015-4678-x
  4. Kwon IG, Cho I, Choi YY, Hyung WJ, Kim CB, Noh SH. Risk factors for complications during surgical treatment of remnant gastric cancer. Gastric Cancer 2015;18:390-396. https://doi.org/10.1007/s10120-014-0369-8
  5. Takahashi K, Yoshikawa T, Morita S, Kinoshita T, Yura M, Otsuki S, et al. Different risks of nodal metastasis by tumor location in remnant gastric cancer after curative gastrectomy for gastric cancer. Gastric Cancer 2020;23:195-201. https://doi.org/10.1007/s10120-019-00989-x
  6. Abe H, Murakami K, Satoh S, Sato R, Kodama M, Arita T, et al. Influence of bile reflux and Helicobacter pylori infection on gastritis in the remnant gastric mucosa after distal gastrectomy. J Gastroenterol 2005;40:563-569. https://doi.org/10.1007/s00535-005-1589-9
  7. Tanigawa N, Nomura E, Niki M, Shinohara H, Nishiguchi K, Okuzawa M, et al. Clinical study to identify specific characteristics of cancer newly developed in the remnant stomach. Gastric Cancer 2002;5:23-28.
  8. Japanese Gastric Cancer Association. Japanese classification of gastric carcinoma: 3rd English edition. Gastric Cancer 2011;14:101-112. https://doi.org/10.1007/s10120-011-0041-5
  9. Lee JH, Chang KK, Yoon C, Tang LH, Strong VE, Yoon SS. Lauren histologic type is the most important factor associated with pattern of recurrence following resection of gastric adenocarcinoma. Ann Surg 2018;267:105-113. https://doi.org/10.1097/SLA.0000000000002040
  10. Honda S, Bando E, Makuuchi R, Tokunaga M, Tanizawa Y, Kawamura T, et al. Effects of initial disease status on lymph flow following gastrectomy in cases of carcinoma in the remnant stomach. Gastric Cancer 2017;20:457-464. https://doi.org/10.1007/s10120-016-0640-2
  11. Han WH, Eom BW, Yoon HM, Kim YW, Kook MC, Ryu KW. The different clinicopathological features of remnant gastric cancer depending on initial disease of partial gastrectomy. Cancers (Basel) 2020;12:E2847.
  12. Kondo K. Duodenogastric reflux and gastric stump carcinoma. Gastric Cancer 2002;5:16-22. https://doi.org/10.1007/s101200200002
  13. Songun I, Putter H, Kranenbarg EM, Sasako M, van de Velde CJ. Surgical treatment of gastric cancer: 15- year follow-up results of the randomised nationwide Dutch D1D2 trial. Lancet Oncol 2010;11:439-449. https://doi.org/10.1016/S1470-2045(10)70070-X
  14. Riihimaki M, Thomsen H, Sundquist K, Sundquist J, Hemminki K. Clinical landscape of cancer metastases. Cancer Med 2018;7:5534-5542. https://doi.org/10.1002/cam4.1697
  15. Langley RR, Fidler IJ. The seed and soil hypothesis revisited--the role of tumor-stroma interactions in metastasis to different organs. Int J Cancer 2011;128:2527-2535. https://doi.org/10.1002/ijc.26031
  16. Fouad YA, Aanei C. Revisiting the hallmarks of cancer. Am J Cancer Res 2017;7:1016-1036.
  17. Riihimaki M, Hemminki A, Sundquist K, Sundquist J, Hemminki K. Metastatic spread in patients with gastric cancer. Oncotarget 2016;7:52307-52316. https://doi.org/10.18632/oncotarget.10740
  18. Park JH, Ryu MH, Kim HJ, Ryoo BY, Yoo C, Park I, et al. Risk factors for selection of patients at high risk of recurrence or death after complete surgical resection in stage I gastric cancer. Gastric Cancer 2016;19:226-233. https://doi.org/10.1007/s10120-015-0464-5
  19. Choi YY, Kwon IG, Lee SK, Kim HK, An JY, Kim HI, et al. Can we apply the same indication of endoscopic submucosal dissection for primary gastric cancer to remnant gastric cancer? Gastric Cancer 2014;17:310-315. https://doi.org/10.1007/s10120-013-0265-7
  20. Liakakos T, Thomakos N, Fine PM, Dervenis C, Young RL. Peritoneal adhesions: etiology, pathophysiology, and clinical significance. Recent advances in prevention and management. Dig Surg 2001;18:260-273. https://doi.org/10.1159/000050149
  21. Stangl-Kremser J, Muto G, Grosso AA, Briganti A, Comperat E, Di Maida F, et al. The impact of lymphovascular invasion in patients treated with radical nephroureterectomy for upper tract urothelial carcinoma: An extensive updated systematic review and meta-analysis. Urol Oncol 2022;40:243-261. https://doi.org/10.1016/j.urolonc.2022.01.014
  22. Takeuchi M, Kawakubo H, Shimada A, Matsuda S, Nakahara T, Mayanagi S, et al. Assessment of lymphatic flow based on the sentinel node concept in early gastric adenocarcinoma that satisfies expanded endoscopic resection criteria. Gastric Cancer 2020;23:531-539. https://doi.org/10.1007/s10120-019-01026-7
  23. Mei Y, Feng T, Yan M, Zhu Z, Zhu Z. Is adjuvant chemotherapy necessary for early gastric cancer? Cancer Biol Med 2021;19:518-532. https://doi.org/10.20892/j.issn.2095-3941.2020.0636
  24. Raffone A, Travaglino A, Raimondo D, Neola D, Maletta M, Santoro A, et al. Lymphovascular space invasion in endometrial carcinoma: a prognostic factor independent from molecular signature. Gynecol Oncol 2022;165:192-197. https://doi.org/10.1016/j.ygyno.2022.01.013